Clinical Trials Browser

Phase 2 × Lung Diseases × Erlotinib Hydrochloride × Clear all

NCT03389256 2018-01-03

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Phase 2 Unknown

Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms